Maibo Pharmaceutical - B (02181.HK) announced its interim performance for the six months ending in June, with revenue of 0.108 billion RMB (the same below), an increase of 146.4% year-on-year. The loss narrowed from 99.999 million yuan in the same period last year to 97.57 million yuan, with a loss per share of 2 fen. No interim dividend will be paid.
《業績》邁博藥業(02181.HK)中期虧損收窄至9,757萬人民幣
Performance: Meibo Pharmaceuticals (02181.HK) narrowed its mid-year loss to 97.57 million RMB.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated